CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$3.63 USD
+0.49 (15.61%)
Updated Jun 13, 2024 03:59 PM ET
After-Market: $3.72 +0.09 (2.48%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 21 - 40 ( 217 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Piclidenoson and Namodenoson Continue With Strong Momentum Going Into 2023; Reit Buy With Post-ADS Adjusted Ratio $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Neutral: Effects 1:10 Reverse Stock Split & Raises $7.5 Million
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Lowering to Neutral from Buy Ahead of Reverse Split
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Raising Our Target from $5.0 to $8.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Third Quarter Results - $10.8M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Can-Fite announces poster presentation highlighting complete response induced by Namodenoson at the American Association for the Study of Liver Diseases
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
New COMFORT Piclidenoson Results Presented at EADV; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Namodenoson Approved for Compassionate Use Romania for HCC
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: European Academy of Dermatology and Venerology Congress
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Can-Fite to submit FDA & EMA Registration Plans for Piclidenoson - Severe Psoriasis
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: COMFORT Pivotal Study Meets Its Primary Endpoint
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Positive Top-Line Results From COMFORT Position Piclidenoson For Pivotal Study; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Namodenoson and Piclidenoson Continue to Achieve Milestones; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Top-Line Psoriasis Data is Coming
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J